Tango Therapeutics, Inc.
Company Stats
- Market Cap
- $4.2B
- as of Sep 30, 2026
- Shares Outstanding
- 168.6M
- Free Float
- 66.2%
Income Statement
- Revenue
- $62.4M
- Operating Income
- -$111.3M
- Net Income
- -$101.6M
- EBITDA
- -$109.0M
- Revenue Growth, 3Y
- 35.9%
- FCF Margin, 3Y Avg
- -288.6%
- FCF Margin, Worst Year
- -327.2%
Cash Flow
- Free Cash Flow
- -$139.9M
- FCF Yield
- -3.3%
- Owner FCF Yield
- -4.0%
Balance Sheet
- Cash & Equivalents
- $112.3M
Returns & Capital
- SBC, 3Y Avg
- $24.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $62.4M | -$139.9M | -224.3% |
| FY2024 | $42.1M | -$132.3M | -314.4% |
| FY2023 | $36.5M | -$119.5M | -327.2% |
| FY2022 | $24.9M | -$116.8M | -469.7% |
| FY2021 | $37.0M | -$61.4M | -165.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges